Reneuron Group (RENE)
RENE Share PerformanceMore
|52 week high||3.8700 15/03/16|
|52 week low||2.2500 04/11/16|
|52 week change||-0.2640 (-9.61%)|
|4 week volume||51,426,081 01/02/17|
Media for (RENE)
Latest News« previous» nextMore
15/02/2017 - 07:00 RNS
RNS Number: 9216W ReNeuron Group plc 15 February 2017 15 February 2017 AIM: RENE RNS REACH ReNeuron Group plc ("ReNeuron" or the "Company") ReNeuron featured in BBC documentary "Andrew Marr: My Brain and Me" ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that its...
07/02/2017 - 14:15 StockMarketWire
Michael Hunt, Financial Director, bought 250,000 shares in the company on the 7th February 2017 at a price of 2.64p. The D...
07/02/2017 - 12:32 RNS
RNS Number: 2499W ReNeuron Group plc 07 February 2017 7 February 2017 AIM: RENE ReNeuron Group plc ("ReNeuron" or the "Company") Director Share Purchase ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, was informed on 7 February 2017 that, on the same day, Michael Hunt , the Company...
01/02/2017 - 11:24 StockMarketWire
Michael Hunt, CFO of ReNeuron Group Plc (RENE) (LSE:RENE) will be giving a presentation at the exclusive Shares Inv...
14/12/2016 - 12:15 RNS
RNS Number: 8537R ReNeuron Group plc 14 December 2016 14 December 2016 AIM: RENE ReNeuron Group plc ("ReNeuron" or the "Company") Director Share Purchase ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, was informed on 14 December 2016 that, on the same day, Olav Helleb, the Company'...
05/12/2016 - 09:40 StockMarketWire
ReNeuron has widened its H1 pretax loss to 8.6m, from a loss of 5.2m. Revenue was 22,000, from 11,000. Research and develo...
05/12/2016 - 09:38 StockMarketWire
ReNeuron Group announces positive data from its Phase II clinical trial (PISCES II) of its CTX cell therapy candidate for s...
05/12/2016 - 07:00 RNS
RNS Number: 8915Q ReNeuron Group plc 05 December 2016 Details are given below of an analyst meeting and webcast at 9.00am this morning 5 December 2016 AIM: RENE ReNeuron Group plc ("ReNeuron" or "the Company") Interim Results for the six months ended 30 September 2016 ReNeuron Group plc (AIM: RENE), a UK-based global leader in the develop...
|Dividend yield||0 %|
Equity Research (RENE)
ReNeuron Group plc
ReNeuron has presented positive Phase II trial data for its CTX cells in chronic stroke patients. Reported data included 15 out of 21 patients having a clinically relevant and sustained response on...
ReNeuron Group plc
ReNeuron has announced the publication of long-term Phase I stroke clinical trial (PISCES-I) data in The Lancet. The data indicate improvements in neurological status and limb function compared with...
ReNeuron Group plc
Investor focus is currently on the readout of ReNeuron’s Phase II stroke disability study with its CTX cells, due in Q416. Alongside this there are a number of other data readouts and progression of...
- 1 of 3
Latest discussion posts More
“Morning Paul. Yes plenty of activity which under any other circumstances would raise the sp. Looks like mates rates set to continue. Still I have topped up on the back of the ...”▼
“Disappointing of course to see the price drop this morning but encouraging to see the substantial buying in response which has been going on for a while now. Beginning to ...”▼
“believe this you'll believe anything! the hubris of man - nevermind economists! http://www.bbc.co.uk/news/business-39039315 lol hindsight will always be there ...”▼
Codes & Symbols
|Symbols||RENE, LSE:RENE, RENE.L, RENE:LN, LON:RENE, XLON:RENE|